Archive of oncology · 2022 · 61 citations · 25 references
MedicineOncologyPharmacotherapyCancer GeneticsMolecular OncologyOncogenesCancer ProgressionColorectal CancerGastrointestinal Cancer PharmacotherapyMelanoma PharmacotherapyOncogene MutationsOncogenic Signaling PathwaysBraf V600 MutationsBraf V600e MutationMitogen-activated Protein Kinase CascadesMitogen-activated Protein Kinase InactivationMolecular Drug ResistanceMutationProtein Kinase InhibitorsProto-oncogene Mutation
Colon cancer is a leading cause of cancer-related deaths worldwide. About 10% of all colon cancer patients are found to have a mutation in BRAF proto-oncogene that arise as a result of a substitution of amino acid valine with glutamate at position 600 (V600E). This specific mutation is also found in melanomas, but at even higher percent ? in up to 60% of patients. A particular category of drugs called BRAF inhibitors, have been developed in order to increase survival. But, while in patients with melanoma this class of drugs work well especially when combined with mitogen-activated protein kinase inhibitors, they have low efficacy in patients with metastatic colorectal cancer suggesting different mechanism of action and development of drug resistance. This review summarise recent findings aimed to highlight events in BRAF mutations in metastatic colorectal cancer.
25
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Mutations of the BRAF gene in human cancer
Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.7K citations
Genetic Alterations during Colorectal-Tumor Development
Bert Vogelstein, Eric R. Fearon, Stanley R. Hamilton et al. · New England Journal of Medicine · 1988 · 6.8K citations
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty, Igor Puzanov, Kevin B. Kim et al. · New England Journal of Medicine · 2010 · 3.5K citations
Medicine, Oncology, Pharmacology +17